FDA plans modest changes to medical device system

Jan 19, 2011 By MATTHEW PERRONE , AP Health Writer

(AP) -- The Food and Drug Administration is laying out plans to update the 35-year-old system used to approve most medical devices, which has been subject to increasing criticism by public safety advocates.

The agency announced a series of changes it plans to make this year, including streamlining the review process for some low-risk devices. But regulators said they will delay a decision on the most drastic proposals, which would give the government new power to police device makers.

Those proposals, widely supported by advocates, included clarifying the FDA's power to revoke approval for products that prove unsafe or ineffective. Another key proposal would have established a new subset of devices that would require more medical data to gain approval.

But those proposals, unveiled for comment last summer, received strong pushback from device companies, and the FDA said in its report "that implementing them may be problematic."

The device industry's chief trade group, AdvaMed, lobbied against the changes, saying they would make device reviews longer and more expensive, hurting innovation and endangering jobs. The group represents most of the largest device firms, including Medtronic Inc., Stryker Corp. and Johnson & Johnson.

Dr. Diana Zuckerman of the National Research Center for Women and Families said the FDA's plan suggests "industry lobbyists won, and the public lost."

"Today's FDA report gives the impression that FDA backed down on several safeguards as a result of unfavorable comments," Zuckerman said in a statement. "FDA decisions should not be based on a popularity contest, especially since lobbyists rig the results"

The FDA said it would wait for the guidance of the Institute of Medicine before making a final decision on more sweeping changes. The nonpartisan expert group advises the federal government on medical policy.

The so-called 510(k) system for devices was created in 1976 to grant speedy approval to devices that are similar to products already on the market. It is popular among manufacturers because it is a faster, cheaper path to market than the review process for novel devices, which must undergo rigorous medical testing. Hip replacements and drug pumps are among the devices cleared under the system.

But FDA critics say that high-risk devices, such as heart pacemakers, are increasingly slipping through the 510(k) process without thorough testing and scrutiny.

About 4,000 devices are cleared every year under the 510(k) system, while about 50 devices are approved under the more stringent system.

Last October the FDA took the unprecedented step of acknowledging that a knee repair device cleared via 510(k) in 2008 should not have made it to market. The FDA's two top device regulators who oversaw the device's review have since left the agency.

Beginning in March the FDA said it will make 25 changes to the 510(k) process, including:

- establishing a database with photos and safety labeling for all devices

- clarifying when companies must submit clinical data for a 510(k) application

- establishing a council of experts within the agency to work on timely device approvals

Explore further: Police seize millions in huge fake Viagra swoop

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA moves toward tighter medical device oversight

Aug 04, 2010

(AP) -- Makers of X-ray machines, drug pumps and other medical devices would have to submit more safety information to win federal approval under a proposal designed to tighten regulation of thousands of products reviewed ...

FDA medical device approvals get external review

Sep 23, 2009

(AP) -- The Food and Drug Administration is asking the government's top medical advisers to review its system for approving certain types of medical devices, which has been criticized by safety advocates and government watchdogs.

Recommended for you

Novartis Japan admits concealing drug side effects

17 hours ago

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

Expression of privilege in vaccine refusal

Aug 27, 2014

Not all students returning to school this month will be up to date on their vaccinations. A new study conducted by Jennifer Reich, a researcher at the University of Colorado Denver, shows that the reasons why children may ...

User comments : 0